×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INMB – inmune bio inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INMB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/16
08:00 am
inmb
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
Low
Report
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
4/1
07:27 am
inmb
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
Medium
Report
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
3/30
11:11 pm
inmb
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
Low
Report
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
3/30
06:53 pm
inmb
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/30
04:00 pm
inmb
INmune Bio Inc. Announces 2025 Results and Provides Business Update
Medium
Report
INmune Bio Inc. Announces 2025 Results and Provides Business Update
3/24
08:00 am
inmb
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
Low
Report
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
3/19
08:00 am
inmb
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
Low
Report
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
3/12
06:32 am
inmb
INmune Bio (INMB) was upgraded by Lucid Cap Mkts from "hold" to "strong-buy".
Medium
Report
INmune Bio (INMB) was upgraded by Lucid Cap Mkts from "hold" to "strong-buy".
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
04:05 pm
inmb
inmune bio inc. - common stock
BEAT
Report
5.8%
inmune bio inc. - common stock
8/7/2025
04:05 pm
inmb
inmune bio inc. - common stock
MISS
Report
-7.9%
inmune bio inc. - common stock
5/8/2025
04:10 pm
inmb
inmune bio inc. - common stock
IN-LINE
Report
-1.7%
inmune bio inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/30
05:31 pm
inmb
Form 10-K Inmune Bio, Inc. For: Dec 31
Medium
Report
Form 10-K Inmune Bio, Inc. For: Dec 31
2/27
09:15 am
inmb
Form 8-K Inmune Bio, Inc. For: Feb 27
Medium
Report
Form 8-K Inmune Bio, Inc. For: Feb 27
2/23
04:06 pm
inmb
Form 8-K Inmune Bio, Inc. For: Feb 23
Medium
Report
Form 8-K Inmune Bio, Inc. For: Feb 23
2/19
04:00 pm
inmb
Form 8-K Inmune Bio, Inc. For: Feb 19
Low
Report
Form 8-K Inmune Bio, Inc. For: Feb 19
2/13
04:01 pm
inmb
Form 8-K Inmune Bio, Inc. For: Feb 10
Low
Report
Form 8-K Inmune Bio, Inc. For: Feb 10
1/27
04:01 pm
inmb
Form 8-K Inmune Bio, Inc. For: Jan 27
High
Report
Form 8-K Inmune Bio, Inc. For: Jan 27
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/11
Form 10-K Inmune Bio, Inc. For: Dec 31
26.3%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
TOP News Decliners
3/11
INmune Bio Inc. (INMB) CEO R.J. Tesi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-29.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: